Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L9KH
|
|||
| Former ID |
DIB013922
|
|||
| Drug Name |
Etrasimod
|
|||
| Synonyms |
APD-334; S1P1 receptor agonists (autoimmune diseases), Arena Pharmaceuticals
Click to Show/Hide
|
|||
| Indication | Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Approved | [1] | |
| Autoimmune diabetes [ICD-11: 5A10] | Phase 2 | [2] | ||
| Pyoderma gangrenosum [ICD-11: EB21] | Phase 2 | [3] | ||
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H26F3NO3
|
|||
| Canonical SMILES |
C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F
|
|||
| InChI |
1S/C26H26F3NO3/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)/t17-/m1/s1
|
|||
| InChIKey |
MVGWUTBTXDYMND-QGZVFWFLSA-N
|
|||
| CAS Number |
CAS 1206123-37-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sphingosine-1-phosphate receptor 1 (S1PR1) | Target Info | Agonist | [1] |
| KEGG Pathway | FoxO signaling pathway | |||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
| S1P3 pathway | ||||
| S1P1 pathway | ||||
| Sphingosine 1-phosphate (S1P) pathway | ||||
| PDGFR-beta signaling pathway | ||||
| Reactome | G alpha (i) signalling events | |||
| Lysosphingolipid and LPA receptors | ||||
| WikiPathways | Signal Transduction of S1P Receptor | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216956 | |||
| REF 2 | ClinicalTrials.gov (NCT02447302) Safety and Efficacy of APD334 in Patients With Ulcerative Colitis. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.